AptarGroup (ATR) Corporate presentation summary

Business overview and strategy

• Global leader in drug delivery and consumer product dosing, dispensing, and protection technologies, serving healthcare and consumer brands worldwide.

• Focus on innovation, sustainability, and transforming ideas into solutions that improve everyday life.

• Operates in pharma, beauty, closures, food, beverage, personal care, and home care markets, with a diversified and resilient portfolio.

• Over 14,000 employees in 20+ countries, with a strong global presence and more than 5,000 customers, including leading brands.

• Strategic priorities include organic growth, talent development, innovation, operational efficiency, and targeted acquisitions.

Financial performance and targets

• FY 2025 reported sales reached $3.78B, up 5% from the prior year, with 2% core sales growth and 2% currency effects.

• FY 2025 adjusted EBITDA was $815M (up 5%), adjusted EPS was $5.74 (down 1%), and free cash flow was $303M, impacted by tax payments and higher working capital.

• Long-term targets: 4-7% core sales growth, 21-23% adjusted EBITDA margin, 12-14% ROIC, 30-40% dividend payout ratio, and 1-3x leverage corridor.

• Pharma segment targets 7-11% core sales growth and 32-36% adjusted EBITDA margin; Beauty targets 3-6% growth and 15-17% margin; Closures targets 4-7% growth and 16-18% margin.

Innovation and product portfolio

• Proprietary drug delivery systems and precision dispensing solutions for pharma, beauty, food, beverage, and personal care.

• Over 7,000 active and pending patents, with a strong innovation pipeline and lifecycle management strategies.

• Digital health platform with patient-facing solutions and partnerships with major pharma companies.

• Active material science solutions enhance product stability, efficacy, and shelf-life.

• Focus on sustainability, including recyclable, reusable, and circular economy solutions.